XAIR: Global Network Expansion Will Drive Long-Term Market Presence

Key Takeaways

• International expansion and partnerships are driving greater market access, positioning the company for sustained revenue growth in advanced respiratory care.
  
• Product innovation and operational efficiencies are improving scalability, margin potential, and revenue stability through recurring contracts and long-term customer relationships.
  
• Heavy reliance on a single core platform, ongoing losses, and competitive pressures expose Beyond Air to revenue volatility, margin risks, and potential shareholder dilution.

Catalysts

A commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform.

• Strong global expansion with distribution partners now covering over 30 countries and access to more than 2 billion people positions Beyond Air to capitalize on the growing demand for advanced respiratory care fueled by aging populations and rising healthcare expenditures, likely driving sustained revenue growth.
  
• Integration into two of the largest U.S. Group Purchasing Organizations (Vizient and Premier) lowers sales cycle friction and improves market access, aligning with the increasing emphasis on non-pharmaceutical interventions in respiratory care and enhancing the company's ability to scale recurring revenues.
  
• Upcoming launch of the second-generation LungFit system, designed for portability and broader hospital use, responds to digital health transformation trends and is expected to significantly boost market share, total nitric oxide volumes, and eventually improve gross and net margins as adoption accelerates.
  
• Substantial operational cost reductions (over 40% YoY decrease in operating expenses and 60% drop in cash burn) have created operating leverage; as new revenues ramp with international and domestic expansion, incremental sales should increasingly flow to earnings.
  
• The transition to multiyear and recurring hospital contracts, together with longer-term customer relationships and expanding use-cases, supports revenue stability and visibility, which is a tailwind for improving margin and earnings quality over time.

Beyond Air Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Beyond Air's revenue will grow by 96.4% annually over the next 3 years.
• Analysts are not forecasting that Beyond Air will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Beyond Air's profit margin will increase from -447.7% to the average US Medical Equipment industry of 12.1% in 3 years.
• If Beyond Air's profit margin were to converge on the industry average, you could expect earnings to reach $6.3 million (and earnings per share of $0.49) by about June 2029, up from -$31.0 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 23.1x on those 2029 earnings, up from -0.1x today. This future PE is lower than the current PE for the US Medical Equipment industry at 24.9x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 12.46%, as per the Simply Wall St company report.

Risks

• Beyond Air remains heavily reliant on one core platform (LungFit PH and its upcoming Gen II version); delays in FDA approval or underperformance in clinical adoption of the Gen II system could significantly constrain revenue growth, limit margin expansion, and increase earnings volatility.
  
• The company continues to post material net losses (Q1 2026 net loss of $7.7 million), with cash and equivalents of just $6.5 million as of June 30, 2025-raising substantial dilution risk if internal projections are missed or costs rise, thus putting pressure on future per-share earnings and overall shareholder returns.
  
• Entry into large US hospital systems via group purchasing organizations (GPOs) like Premier and Vizient may compress ASPs and extend sales cycles as buyers gain negotiating leverage, posing potential headwinds to sustained top-line growth and long-term gross margins.
  
• International expansion is still in early, unproven stages; sales so far are primarily to distribution partners for demonstration/training, and actual hospital adoption is likely to lag by several quarters, creating long cycles before material recurring revenues may be realized and increasing revenue forecasting risk.
  
• Industry-wide pressures around healthcare cost containment and rising competition from both large device manufacturers and agile startups in respiratory care could threaten Beyond Air's market share, compress pricing power, and undermine net margin improvement over time.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $8.0 for Beyond Air based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $14.0, and the most bearish reporting a price target of just $2.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $52.4 million, earnings will come to $6.3 million, and it would be trading on a PE ratio of 23.1x, assuming you use a discount rate of 12.5%.
• Given the current share price of $0.35, the analyst price target of $8.0 is 95.7% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.